1887

Abstract

Cell-mediated immune responses to hepatitis C virus (HCV) proteins play a key role in recovery from infection. The NS3 protein of HCV is of special interest, since it is one of the most conserved proteins and NS3-specific immune responses are stronger and more frequently observed in patients resolving the infection than in chronically infected patients. Since these characteristics make NS3 an attractive vaccine candidate, the objective of this study was to optimize NS3-specific immune responses. Results from this group first demonstrated that a plasmid enriched with 24 CpG motifs (pBISIA24-NS3) tends to induce the strongest and most consistent Th1-biased immune response. Subsequently, it was shown that NS3 formulated with CpG oligodeoxynucleotide and Quil A (rNS3+CpG+Quil A) adjuvants induces a balanced immune response in mice, whereas rNS3 combined with either CpG or Quil A elicits a Th2-biased response. To further enhance NS3-specific cell-mediated immune responses, a vaccination regime consisting of priming with pBISIA24-NS3, followed by boosting with rNS3+CpG+Quil A, was explored in mice and pigs. When compared to immunization with rNS3+CpG+Quil A, this regime shifted the immune response to a Th1-type response and, accordingly, enhanced MHC I-restricted killing by cytotoxic T lymphocytes in mice. Although immunization with pBISIA24-NS3 also induced a Th1-biased response, including cytotoxicity in the mice, the humoral response was significantly lower than that induced by the DNA prime–protein boost regime. These results demonstrate the advantage of a DNA prime–protein boost approach in inducing a strong NS3-specific cell-mediated, as well as humoral, immune response, in both inbred laboratory and outbred large animal species.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.79821-0
2004-06-01
2019-12-13
Loading full text...

Full text loading...

/deliver/fulltext/jgv/85/6/vir851533.html?itemId=/content/journal/jgv/10.1099/vir.0.79821-0&mimeType=html&fmt=ahah

References

  1. Acosta-Rivero, N., Alvarez-Obregon, J. C., Musacchio, A., Falcon, V., Duenas-Carrera, S., Marante, J., Menendez, I. & Morales, J. ( 2002; ). In vitro self-assembled HCV core virus-like particles induce a strong antibody immune response in sheep. Biochem Biophys Res Commun 290, 300–304.[CrossRef]
    [Google Scholar]
  2. Anwer, K., Earle, K. A., Shi, M. & 11 other authors ( 1999; ). Synergistic effect of formulated plasmid and needle-free injection for genetic vaccines. Pharm Res 16, 889–895.[CrossRef]
    [Google Scholar]
  3. Baca-Estrada, M. E., Snider, M., Tikoo, S. K., Harland, R., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. ( 1996; ). Immunogenicity of bovine herpesvirus 1 glycoprotein D in mice: effect of antigen form on the induction of cellular and humoral immune responses. Viral Immunol 9, 11–22.[CrossRef]
    [Google Scholar]
  4. Barr, I. G. & Mitchell, G. F. ( 1996; ). ISCOMs (immunostimulating complexes): the first decade. Immunol Cell Biol 74, 8–25.[CrossRef]
    [Google Scholar]
  5. Battegay, M., Fikes, J., Di Bisceglie, A. M. & 11 other authors ( 1995; ). Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2·1 molecules. J Virol 69, 2462–2470.
    [Google Scholar]
  6. Boyer, J. D., Wang, B., Ugen, K. E. & 9 other authors ( 1996; ). In vivo protective anti-HIV immune responses in non-human primates through DNA immunization. J Med Primatol 25, 242–250.[CrossRef]
    [Google Scholar]
  7. Brinster, C., Chen, M., Boucreux, D., Paranhos-Baccala, G., Liljestrom, P., Lemmonier, F. & Inchauspe, G. ( 2002; ). Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. J Gen Virol 83, 369–381.
    [Google Scholar]
  8. Bryan, L. A., Griebel, P. J., Haines, D. M., Davis, W. C. & Allen, J. R. ( 1988; ). Immunocytochemical identification of bovine Langerhans cells by use of a monoclonal antibody directed against class II MHC antigens. J Histochem Cytochem 36, 991–995.[CrossRef]
    [Google Scholar]
  9. Bukh, J., Forns, X., Emerson, S. U. & Purcell, R. H. ( 2001; ). Studies of hepatitis C virus in chimpanzees and their importance for vaccine development. Intervirology 44, 132–142.[CrossRef]
    [Google Scholar]
  10. Choo, Q. L., Kuo, G., Ralston, R. & 15 other authors ( 1994; ). Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A 91, 1294–1298.[CrossRef]
    [Google Scholar]
  11. Chu, R. S., Targoni, O. S., Krieg, A. M., Lehmann, P. V. & Harding, C. V. ( 1997; ). CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186, 1623–1631.[CrossRef]
    [Google Scholar]
  12. Cooper, S., Erickson, A. L., Adams, E. J., Kansopon, J., Weiner, A. J., Chien, D. Y., Houghton, M., Parham, P. & Walker, C. M. ( 1999; ). Analysis of a successful immune response against hepatitis C virus. Immunity 10, 439–449.[CrossRef]
    [Google Scholar]
  13. Cox, J. C. & Coulter, A. R. ( 1997; ). Adjuvants – a classification and review of their modes of action. Vaccine 15, 248–256.[CrossRef]
    [Google Scholar]
  14. Davis, H. L. ( 2000; ). Use of CpG DNA for enhancing specific immune responses. Curr Top Microbiol Immunol 247, 171–183.
    [Google Scholar]
  15. Davis, H. L., Weeratna, R., Waldschmidt, T. J., Tygrett, L., Schorr, J. & Krieg, A. M. ( 1998; ). CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 160, 870–876.
    [Google Scholar]
  16. Davis, H. L., Suparto, I. I., Weeratna, R. R. & 10 other authors ( 2000; ). CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 18, 1920–1924.[CrossRef]
    [Google Scholar]
  17. Diepolder, H. M., Gerlach, J. T., Zachoval, R. & 9 other authors (1997; ). Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 71, 6011–6019.
    [Google Scholar]
  18. Donnelly, J. J., Friedman, A., Martinez, D., Montgomery, D. L., Shiver, J. W., Motzel, S. L., Ulmer, J. B. & Liu, M. A. ( 1995; ). Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med 1, 583–587.[CrossRef]
    [Google Scholar]
  19. Duenas-Carrera, S., Vina, A., Martinez, R. & 7 other authors ( 2004; ). Immunization with a DNA vaccine encoding the hepatitis-C-virus structural antigens elicits a specific immune response against the capsid and envelope proteins in rabbits and Mecaca irus (crab-eating macaque monkeys). Biotechnol Appl Biochem 39, 249–255.[CrossRef]
    [Google Scholar]
  20. Encke, J., zu Putlitz, J., Geissler, M. & Wands, J. R. ( 1998; ). Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. J Immunol 161, 4917–4923.
    [Google Scholar]
  21. Farci, P., Alter, H. J., Wong, D. C., Miller, R. H., Govindarajan, S., Engle, R., Shapiro, M. & Purcell, R. H. ( 1994; ). Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A 91, 7792–7796.[CrossRef]
    [Google Scholar]
  22. Fynan, E. F., Webster, R. G., Fuller, D. H., Haynes, J. R., Santoro, J. C. & Robinson, H. L. ( 1993; ). DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A 90, 11478–11482.[CrossRef]
    [Google Scholar]
  23. Geissler, M., Gesien, A., Tokushige, K. & Wands, J. R. ( 1997; ). Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol 158, 1231–1237.
    [Google Scholar]
  24. Grakoui, A., Wychowski, C., Lin, C., Feinstone, S. M. & Rice, C. M. ( 1993; ). Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 67, 1385–1395.
    [Google Scholar]
  25. Hartmann, G., Weeratna, R. D., Ballas, Z. K. & 9 other authors ( 2000; ). Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 164, 1617–1624.[CrossRef]
    [Google Scholar]
  26. Hijikata, M., Kato, N., Ootsuyama, Y., Nakagawa, M. & Shimotohno, K. ( 1991; ). Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci U S A 88, 5547–5551.[CrossRef]
    [Google Scholar]
  27. Hoofnagle, J. H. ( 1997; ). Hepatitis C: the clinical spectrum of disease. Hepatology 26, 15S–20S.[CrossRef]
    [Google Scholar]
  28. Inchauspe, G. & Feinstone, S. ( 2003; ). Development of a hepatitis C virus vaccine. Clin Liver Dis 7, 243–259.[CrossRef]
    [Google Scholar]
  29. Ioannou, X. P., Griebel, P., Hecker, R., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. ( 2002a; ). The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. J Virol 76, 9002–9010.[CrossRef]
    [Google Scholar]
  30. Ioannou, X. P., Gomis, S. M., Karvonen, B., Hecker, R., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. ( 2002b; ). CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. Vaccine 21, 127–137.[CrossRef]
    [Google Scholar]
  31. Ioannou, X. P., Griebel, P., Mena, A., Gomis, S. M., Godson, D. L., Mutwiri, G., Hecker, R., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. ( 2003; ). Safety of CpG oligodeoxynucleotides in veterinary species. Antisense Nucleic Acid Drug Dev 13, 157–167.[CrossRef]
    [Google Scholar]
  32. Jiao, X., Wang, R. Y., Feng, Z., Alter, H. J. & Shih, J. W. ( 2003; ). Modulation of cellular immune response against hepatitis C virus nonstructural protein 3 by cationic liposome encapsulated DNA immunization. Hepatology 37, 452–460.[CrossRef]
    [Google Scholar]
  33. Jin, L. & Peterson, D. L. ( 1995; ). Expression, isolation, and characterization of the hepatitis C virus ATPase/RNA helicase. Arch Biochem Biophys 323, 47–53.[CrossRef]
    [Google Scholar]
  34. Kim, J. J., Yang, J. S., Manson, K. H. & Weiner, D. B. ( 2001; ). Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-gamma, or IL-4 gene adjuvants. Vaccine 19, 2496–2505.[CrossRef]
    [Google Scholar]
  35. Klinman, D. M. ( 2003; ). CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2, 305–315.[CrossRef]
    [Google Scholar]
  36. Klinman, D. M., Ishii, K. J. & Verthelyi, D. ( 2000; ). CpG DNA augments the immunogenicity of plasmid DNA vaccines. Curr Top Microbiol Immunol 247, 131–142.
    [Google Scholar]
  37. Krieg, A. M., Yi, A. K., Schorr, J. & Davis, H. L. ( 1998; ). The role of CpG dinucleotides in DNA vaccines. Trends Microbiol 6, 23–27.[CrossRef]
    [Google Scholar]
  38. Kurokohchi, K., Akatsuka, T., Pendleton, C. D., Takamizawa, A., Nishioka, M., Battegay, M., Feinstone, S. M. & Berzofsky, J. A. ( 1996; ). Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region. J Virol 70, 232–240.
    [Google Scholar]
  39. Lazdina, U., Hultgren, C., Frelin, L. & 8 other authors ( 2001; ). Humoral and CD4+ T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th1-like responses more effectively as a DNA-based immunogen than as a recombinant protein. J Gen Virol 82, 1299–1308.
    [Google Scholar]
  40. Lewis, P. J., van Drunen Littel-van den Hurk, S. & Babiuk, L. A. ( 1999; ). Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response. J Virol 73, 10214–10223.
    [Google Scholar]
  41. Manickan, E., Karem, K. L. & Rouse, B. T. ( 1997; ). DNA vaccines – a modern gimmick or a boon to vaccinology? Crit Rev Immunol 17, 139–154.[CrossRef]
    [Google Scholar]
  42. Pancholi, P., Perkus, M., Tricoche, N., Liu, Q. & Prince, A. M. ( 2003; ). DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV–vaccinia virus infection in HLA-A2.1-transgenic mice. J Virol 77, 382–390.[CrossRef]
    [Google Scholar]
  43. Pontarollo, R. A., Babiuk, L. A., Hecker, R. & Van Drunen Littel-Van Den Hurk, S. ( 2002; ). Augmentation of cellular immune responses to bovine herpesvirus-1 glycoprotein D by vaccination with CpG-enhanced plasmid vectors. J Gen Virol 83, 2973–2981.
    [Google Scholar]
  44. Poynard, T., Marcellin, P., Lee, S. S. & 8 other authors ( 1998; ). Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352, 1426–1432.[CrossRef]
    [Google Scholar]
  45. Rankin, R., Pontarollo, R., Ioannou, X., Krieg, A. M., Hecker, R., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. ( 2001; ). CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev 11, 333–340.[CrossRef]
    [Google Scholar]
  46. Rankin, R., Pontarollo, R., Gomis, S. & 7 other authors ( 2002; ). CpG-containing oligodeoxynucleotides augment and switch the immune responses of cattle to bovine herpesvirus-1 glycoprotein D. Vaccine 20, 3014–3022.[CrossRef]
    [Google Scholar]
  47. Raz, E., Tighe, H., Sato, Y., Corr, M., Dudler, J. A., Roman, M., Swain, S. L., Spiegelberg, H. L. & Carson, D. A. ( 1996; ). Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci U S A 93, 5141–5145.[CrossRef]
    [Google Scholar]
  48. Rimmelzwaan, G. F. & Osterhaus, A. D. ( 1995; ). A novel generation of viral vaccines based on the ISCOM matrix. Pharm Biotechnol 6, 543–558.
    [Google Scholar]
  49. Saito, I., Miyamura, T., Ohbayashi, A. & 10 other authors ( 1990; ). Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A 87, 6547–6549.[CrossRef]
    [Google Scholar]
  50. Samani, T. D., Jolles, B. & Laigle, A. ( 2001; ). Best minimally modified antisense oligonucleotides according to cell nuclease activity. Antisense Nucleic Acid Drug Dev 11, 129–136.[CrossRef]
    [Google Scholar]
  51. Shimizu, Y. K., Feinstone, S. M., Kohara, M., Purcell, R. H. & Yoshikura, H. ( 1996; ). Hepatitis C virus: detection of intracellular virus particles by electron microscopy. Hepatology 23, 205–209.[CrossRef]
    [Google Scholar]
  52. Song, M. K., Lee, S. W., Suh, Y. S., Lee, K. J. & Sung, Y. C. ( 2000; ). Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice. J Virol 74, 2920–2925.[CrossRef]
    [Google Scholar]
  53. Stittelaar, K. J., Boes, J., Kersten, G. F. & 8 other authors ( 2000; ). In vivo antibody response and in vitro CTL activation induced by selected measles vaccine candidates, prepared with purified Quil A components. Vaccine 18, 2482–2493.[CrossRef]
    [Google Scholar]
  54. Takaki, A., Wiese, M., Maertens, G., Depla, E., Seifert, U., Liebetrau, A., Miller, J. L., Manns, M. P. & Rehermann, B. ( 2000; ). Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 6, 578–582.[CrossRef]
    [Google Scholar]
  55. Tedeschi, V., Akatsuka, T., Shih, J. W., Battegay, M. & Feinstone, S. M. ( 1997; ). A specific antibody response to HCV E2 elicited in mice by intramuscular inoculation of plasmid DNA containing coding sequences for E2. Hepatology 25, 459–462.[CrossRef]
    [Google Scholar]
  56. Thimme, R., Oldach, D., Chang, K. M., Steiger, C., Ray, S. C. & Chisari, F. V. ( 2001; ). Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194, 1395–1406.[CrossRef]
    [Google Scholar]
  57. Ulmer, J. B., Donnelly, J. J., Parker, S. E. & 7 other authors ( 1993; ). Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259, 1745–1749.[CrossRef]
    [Google Scholar]
  58. Wedemeyer, H., Gagneten, S., Davis, A., Bartenschlager, R., Feinstone, S. & Rehermann, B. ( 2001; ). Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse model. Gastroenterology 121, 1158–1166.[CrossRef]
    [Google Scholar]
  59. You, Z., Huang, X., Hester, J., Toh, H. C. & Chen, S. Y. ( 2001; ). Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res 61, 3704–3711.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.79821-0
Loading
/content/journal/jgv/10.1099/vir.0.79821-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error